The Anti-Infectives Division focuses on the development, manufacturing, and distribution of pharmaceutical products used in the prevention and treatment of infectious diseases. Operating under GMP-certified facilities and in compliance with DRAP regulations and the Drug Licensing Management (DML) Rules 2019, the division delivers medicines that meet stringent standards of quality, safety, and efficacy.
The division's portfolio addresses infections affecting the respiratory tract, urinary tract, gastrointestinal tract, skin and soft tissues, and other bacterial conditions. Through a commitment to innovation, quality assurance, and patient care, the division provides healthcare professionals with trusted therapeutic options for managing both common and complex infections.
Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic indicated for the treatment of various bacterial infections, including urinary tract infections, respiratory tract infections, gastrointestinal infections, skin and soft tissue infections, and certain systemic infections. It provides effective antibacterial activity against a wide range of Gram-positive and Gram-negative pathogens, supporting rapid infection control and patient recovery.